Research programme: erythrocyte-encapsulated therapeutics - EryDel

Drug Profile

Research programme: erythrocyte-encapsulated therapeutics - EryDel

Alternative Names: Erythrocyte-encapsulated PAL - EryDel; Erythrocyte-encapsulated phenylalanine ammonia-lyase - EryDel; PAL erythrocyte-encapsulated - EryDel; Phenylalanine ammonia-lyase erythrocyte-encapsulated - EryDel

Latest Information Update: 06 Sep 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator EryDel
  • Developer EryDel; University of Rome; University of Urbino
  • Class Ammonia lyases
  • Mechanism of Action Phenylalanine ammonia lyase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Phenylketonuria

Most Recent Events

  • 05 Sep 2013 Preclinical trials in Phenylketonuria in Italy (Intracoronary)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top